v3.26.1
Note 7 - Goodwill and Other Intangible Assets
 6 Months Ended
Jun. 30, 2026
Notes to Financial Statements  
Intangible Asset [Text Block]

Note 7. Goodwill and Other Intangible Assets

 

The Company's carrying amount of goodwill in the condensed consolidated balance sheet as of  June 30, 2026 represents the excess fair value of the consideration transferred over the fair value of the identifiable net assets acquired and liabilities assumed in the acquisition of FLYTE. See Note 3, Business Combinations, for additional information.

 

The following table summarizes the Company’s intangible assets as of  June 30, 2026 (in thousands):

 

  

Estimated

             
  

Useful Life

  

Gross Carrying

  

Accumulated

  

Net Carrying

 
  

( Years)

  

Amount

  

Amortization

  

Value

 

Amortized intangible assets:

                
                 

Cardiac electrophysiology segment

                

Developed technology ‐ VIVO

  10  $170  $(9) $161 

Developed technology ‐ LockeT

  14   18,770   (4,692)  14,078 

Customer relationships

  6   62   (36)  26 

Trademarks/trade names ‐ VIVO

  10   14   (1)  13 

Trademarks/trade names ‐ LockeT

  9   409   (159)  250 
      $19,425  $(4,897) $14,528 

Private aviation segment

                

Applications

  5   200   (13)  187 

Trademarks/ trade names

  15   1,300   (27)  1,273 

Customer list/ relationships

  15   200   (4)  196 
      $1,700  $(44) $1,656 
      $21,125  $(4,941) $16,184 

Indefinite life intangible assets:

                

Private aviation segment

                

Goodwill

  —   12,962   —   12,962 

FAA Part 135 Operating Certificate

  —   2,417   —   2,417 
                 

Total

     $36,504  $(4,941) $31,563 

 

The following table summarizes the Company’s intangible assets as of  December 31, 2025 (in thousands):

 

  

Estimated

             
  

Useful Life

  

Gross Carrying

  

Accumulated

  

Net Carrying

 
  

( Years)

  

Amount

  

Amortization

  

Value

 

Amortized intangible assets:

                
                 

Cardiac electrophysiology segment

                

Developed technology ‐ VIVO

  15  $170  $—  $170 

Developed technology ‐ LockeT

  14   18,770   (4,022)  14,748 

Customer relationships

  6   62   (31)  31 

Trademarks/trade names ‐ VIVO

  9   14   —   14 

Trademarks/trade names ‐ LockeT

  9   409   (136)  273 
      $19,425  $(4,189) $15,236 

 

The estimated future amortization expense for the next five years and thereafter is as follows (in thousands):

 

  

Future

 
  

Amortization

 

Years ending December 31,

 

Expense

 

Remainder of 2026

 $779 

2027

  1,555 

2028

  1,555 

2029

  1,545 

2030

  1,545 

Thereafter

  9,205 

Total

 $16,184 

 

The Company uses the straight-line method to determine amortization expense for its definite lived intangible assets. Amortization expense, included within selling, general and administrative expenses in the condensed consolidated statements of operations, for the Company's intangible assets was $0.4 million and $0.5 million for the three months ended  June 30, 2026 and 2025, respectively, and $0.8 million and $1 million for the six months ended June 30, 2026 and 2025, respectively.